JAN 1 8 2005 65

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT EXAMINING OPERATION

Applicant(s): Reddy Bandi Parthasaradhi, et al

Serial No: 10/509,139

Group Art Unit:

Filed: September 27, 2004

Examiner:

Att. Docket No.: H1089/20010

Confirmation No.:

For: NOVEL CRYSTALLINE FORMS OF (S) - CITALOPRAM OXALATE

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. No representation is made that the reference(s) is/are prior art with respect to this application.

This Information Disclosure Statement is being filed within three months of the filing date of a national application other than a CPA under 37 CFR § 1.53(d), within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application, before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of an RCE under 37 CFR § 1.114. No certification or fee is required. 37 CFR § 1.97(b).

Application No. 10/509,139 IDS dated January 12, 2005

January 12, 2005

Please charge or credit our Account No. 03-0075 as necessary to effect entry and/or ensure consideration of this submission.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD

By\_

Robert S. Silver
Registration No. 35,681
Customer No. 03000
(215) 567-2010
Attorneys for Applicant(s)

. 9 200	Presentype a p				sons are requ	ired to resp	pond to a	collection (	Approved U.S. Patent and Trademark f information unless it contains a valid	for use through	10/31/	or PTO/SB/O8A ( 12002. OMB 065 MENT OF COMM	1-0031			
PRATE TRADE	A Destitute	for Fo	m 1449A	PTO .						Complete if Known Number 10/509,139						
1000		INFO	<b>DRMA</b>	TION I	DISCL	osu	Application Number									
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT								Filing Date	September 27, 2004						
		``			t as neces			First Named Inventor	Reddy Bandi Parthasaradhi, et al							
•							Group Art Unit									
							Examiner Name									
	Shee	t	1	1 of			1		Attorney Docket Number	H1089/2	20010	)				
			ite No.	U.S. Patent Docu			U.S. PATENT DOC		Name of Patentee or Applicant of Cited Document		Date of Publication of Cited Document MM-DD-YYYY					
	FOREIGN PATENT DOCUMENTS															
	Examiner Initials*	Cite No.	Office	Foreign Patent Document Office Number			Kind Code (If known)		e of Patentee or Applicant of Cited Document			Date of Publication of Cited Document T MM-DD-YYYY				
			ļ	EP 0347066		ļ			ndbeck							
			1	WO 03	/011278			H. Lu	ndbeck				<u>.</u>			
			-						·							

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
		· ·	
		PCT INTERNATIONAL SEARCH REPORT DATED OCTOBER 22, 2003	
-			
EVALUED		DATE CONCIDENCE	

EXAMINER DATE CONSIDERED

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.